Business Wire

WALKOUT

9.12.2021 18:55:13 CET | Business Wire | Press release

Share
Machsanei Hashuk Integrates WalkOut’s Smart-cart Solution in All Its Branches

The Israeli company WalkOut , the developer of an autonomous end-to-end frictionless shopping solution, announces an extensive cooperation agreement with Machsanei Hashuk , one of the largest supermarket chains in Israel. As part of the agreement, the chain will implement the fully autonomous checkout solution, considered the most accurate in the world's retail industry, in all 62 of its branches. Its deployment will begin as early as next month.

Although 61 percent of shoppers would prefer to purchase brands that also have a physical location, over 70 percent of shoppers report that standing in line for checkouts is frustrating and detracts from the shopping experience. Until the development of WalkOut’s solution, no system has accompanied the customer throughout the entire purchase, which includes actual checkout.

WalkOut’s retrofit smartcart solution offers a revolution in the shopping experience that addresses two main challenges that marketing chains face in the physical buying process.
The first is related to waiting in long queues at the checkout. The second is the inability to create a personalized shopping experience for each customer.

The company’s first-ever truly seamless retrofitted solution in the retail industry requires no costly infrastructural changes to the store, while other solutions require the retailer to purchase new carts and most rely on barcode scanners and scales for item recognition. The mountable cart device's multiple high-precision cameras, which utilize many different proprietary algorithms to accurately recognize products, identify the items as shoppers load or remove them with 99.2 percent accuracy.

WalkOut’s edge computing and machine-vision algorithms also curtail the need for costly on-cloud servers and high-bandwidth internet support. This use of single-sensor architecture and edge-computing allows retail stores to operate a much more robust and cost-effective solution. Through a large touchscreen, the device also communicates with the customer to offer personalized recommendations, store navigation, supplementary product information, and relevant promotions based on the shopper's history and location in the store.

"Connecting to one of the largest retail chains in Israel is an exciting opportunity and an important milestone for us," says Assaf Gedalia, CEO and Co-Founder of WalkOut. “The solution is futuristic, personalized, and at the same time preserves the customer's privacy."

"As a chain that advocates innovative technologies, we wanted to offer our customers significant savings in waiting times at the checkouts and provide a more personal, accessible and efficient shopping experience," said Shalom Naaman, CEO and Owner of Machsanei Hashuk. "The WalkOut solution will significantly shorten the length of stay in the branches, help maximize our operational efficiency, and allow us to offer one of the most advanced shopping experiences in the world."

About WalkOut
WalkOut , founded in 2018, has set itself the goal of changing the way consumers purchase products in physical stores by placing the checkout directly on the shopping cart. The company's solution is based on machine vision technology capable of identifying any item placed or removed from the cart and calculating it in the final payment. In this way, the cart eliminates the need for a checkout and reduces the duration of the payment process to a minimum. The WalkOut solution includes a large touch screen located on the cart and combines a personalized shopping experience with offers and promotions based on each consumer's preferences, complementary products and the location of the products in the store. The WalkOut system is modular and can be installed on existing carts in stores without the need for significant changes on the part of the store.

About Machsanei Hashuk
Machsanei Hashuk is a leading marketing chain owned and managed by the Naaman & Cohen families that was first established in 1996 in the city of Beer Sheva. The chain currently has 62 branches nationwide from Safed to Eilat. In 2019, the chain acquired Co-op, and in doing so became one of the largest leading marketing chains in Israel. Co-op branches have since been converted into "Machsanei Hashuk sheli''. The chain operates an advanced and accessible online site, in addition to its branches. It also offers its own Wincard+ credit card, in cooperation with Max, which combines regular card rewards with the chain's own promotions. Machsanei Hashuk operates a strong and active customer club with more than 400,000 loyal customers.
The chain is the official sponsor of the football team "Hapoel Machsanei Hashuk Beer-Sheva.” For more information, visit https://www.mck.co.il/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye